Latest news with #SunPharmaceuticalIndustries
&w=3840&q=100)
Business Standard
an hour ago
- Business
- Business Standard
Sun Pharma halts development of SCD-044 drug after trial disappointment
Sun Pharmaceutical Industries on Tuesday announced that it will discontinue development of its experimental oral drug, SCD-044, following disappointing results in Phase 2 clinical trials for the treatment of moderate to severe psoriasis and atopic dermatitis (eczema). The trial did not achieve the primary objective: a 75 per cent improvement in the EASI (Eczema Area and Severity Index) score by Week 16, the company said. The Phase 2 clinical trial enrolled 250 patients and compared three different dosages of SCD-044 with a placebo. The study followed a randomised, double-blind, placebo-controlled design—standard methodology intended to minimise bias in clinical research. 'While we are disappointed with the top-line results of the clinical trials, we would like to thank all the psoriasis and atopic dermatitis patients, the healthcare professionals and administrators who participated in these pivotal clinical trials,' said Dr Marek Honczarenko, Senior Vice-President and Head of Global Specialty Development at Sun Pharma. Shares of Sun Pharmaceutical closed at ₹1,667.65 on Tuesday, down ₹7.25 or 0.43 per cent. In the fourth quarter of FY25, the company reported a 19 per cent year-on-year decline in net profit to ₹2,153.9 crore, compared with ₹2,658.74 crore in the same quarter of the previous fiscal.
India.com
5 hours ago
- Business
- India.com
Meet woman, an Indian, heir to Rs 4000000000000 business, she is…, her business is…
Vidhi Shanghvi, Sun Pharma Vidhi Shanghvi is the daughter of Dilip Shanghvi. She plays an important role in Sun Pharmaceutical Industries along with brother Aalok Shanghvi. The healthcare business is of Rs 4.35 lakh crore. She did bachelor's in Economics from the Wharton School of the University of Pennsylvania. As per Forbes, Dilip Shanghvi is India's richest healthcare billionaire, with a net worth of around $29.2 billion as of December 15, 2024. Connection To Mukesh Ambani Vidhi is married to Vivek Salgaocar who is son of Goan industrialists Shiv and Ranjana Salgaocar. The Salgaoncars are connected to the Ambanis according to the Economic Times report. One of Mukesh and Anil Ambanis' sisters, Deepti, is married to Dattaraj Salgaocar, brother of Shiv Salgaoncar. Vidhi is the Vice President and Head of Consumer Healthcare, Nutrition, and India Distribution in Sun Pharma. She also developed Sun Pharma like an MNC for more than 10 years. The report also said that Vidhi is a non-executive director at Sun Pharma Advanced Research Company, SPARC is Sun Pharma's subsidiary deals in clinical-stage biopharmaceutical products. Vidhi works for mental health related issues and has founded a non-profit organisation which helps the people to work on their mental health and provide solutions. Sun Pharma Industries According to the official website, Sun Pharmaceutical Industries is the fourth largest specialty generic pharmaceutical company in the world. It earns global revenues of $ 5.4 billion. It has 43 manufacturing facilities, and provides 'high-quality, affordable medicines, trusted by healthcare professionals and patients', to more than 100 countries across the globe.
Time of India
2 days ago
- Business
- Time of India
New launches to drive Sun Pharma's future growth; PAT may take a hit by tax surge
Sun Pharmaceutical Industries has underperformed the BSE Healthcare index over a one-month and three-month periods amid the likely pressure on profitability in the coming quarters. While the company expects to retain the revenue growth momentum for FY26 after clocking 8% growth in FY25, its plan to spend over $100 million in marketing and promotion of specialty products is expected to dent profitability for the current fiscal year. Analysts have slashed FY26 EPS targets by 3-8%. The company's net profit fell by 19% year-on-year to Rs2,149.9 crore for the March quarter due to higher tax outgo. Revenue grew by 8% to Rs12,958.8 crore. The tax expense for the quarter was Rs1,093.7 crore compared to Rs148.9 crore a year ago. The company expects the tax expense to increase further in FY26, due to exhaustion of tax loss from previous accounting periods. The operating margin before depreciation and amortisation (EBITDA margin) improved to 28.7% in the March 2025 quarter from 25.3% in the year-ago quarter. For the full year, the company's revenue and net profit grew by 9% and 14% to Rs52,041.3 crore and Rs10,929 crore respectively. The research & development (R&D) expense was Rs3,248.4 crore for FY25, representing 6.4% of sales. It is expected to be 6-8% of sales for next fiscal year. The pharma company has guided for a mid-to-high single digit year-on-year revenue growth in FY26. The company expanded market share in the domestic formulations business to 8.3% in the March quarter from 8%a year ago. In the September 2025 quarter, Sun Pharma is expected to launch Leqselvi (deuruxolitinib),which is used to treat severe alopecia areata, a type of hair loss. Elara Capital estimates the drug to be more than $200million product in three-four years. In FY26, the company also plans to launch Unloxcyt (cosibelimab), a drug developed by the US based Checkpoint Therapeutics, which it acquired in March 2025 for $355 million. The company is seeking partners to further develop and commercialize MM-II (Large Liposomes of DPPC and DMPC) for select geographies. Phase 3 clinical trials are underway for this drug. 'It has been implementing efforts to not only expand offerings but also enhance marketing franchise in regulated markets for differentiated products,' Motilal Oswal Financial Services said in a report. The brokerage has reduced its earnings estimates by 3% and 1% for FY26 and FY27, considering the additional expense on specialty products marketing . It expects earnings to grow by 17% annually FY25-27. It has maintained 'BUY' with a target price of Rs2,000. On Friday, the stock was last traded at Rs1,678.3 on the BSE.
Business Standard
2 days ago
- Business
- Business Standard
Sun Pharma lines up $100 mn to commercialise niche products in FY26
Sun Pharmaceutical Industries has lined up a $100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 million. Elaborating on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi said. The drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added.
Economic Times
2 days ago
- Business
- Economic Times
Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
Sun Pharmaceutical Industries has lined up a USD 100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. ADVERTISEMENT The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. ADVERTISEMENT In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. ADVERTISEMENT "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. ADVERTISEMENT "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. ADVERTISEMENT Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added. (You can now subscribe to our Economic Times WhatsApp channel)
